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Abstract: Venous thromboembolism (VTE), including both deep venous thrombosis (DVT) and
pulmonary embolism (PE), is a major complication of musculoskeletal surgery in general, and the risk is
heightened in musculoskeletal oncology surgery. Despite the well-known association between cancer and
VTE, the mechanism promoting this pathology is not entirely well understood. It is estimated that nearly
all cancer patients will experience from some form of VTE, whether or not clinically relevant, during the
course of their disease. Nonetheless, numerous studies have analyzed the occurrence and prevention of VTE
in patients with cardiovascular disease or suffering trauma, but very few have specifically examined the safety
or efficacy of preventing VTE in cancer patients with metastatic skeletal disease. This review will examine
the various types of prophylactic treatment, timing of administration, risk stratification for determining the
appropriate course of anticoagulation (AC), and discuss current views on chemical prophylaxes relativity
to wound complications and excessive bleeding in orthopedic oncology patients. Overall, careful choice of
anticoagulant and timing of administration must be made in order to avoid bleeding complications. A risk
stratification system to determine which chemical prophylaxis to administered could be beneficial in both
reducing the occurrence of VTE and decreasing associated wound complications or mortality. Further study
should be conducted to tailor chemical prophylaxes recommendations to this largely affected population and
effectively reduce the occurrence of VTE.
Keywords: Deep venous thrombosis (DVT); orthopedic oncology; venous thromboembolism; musculoskeletal
oncology
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Introduction
Venous thromboembolism (VTE), including both deep
venous thrombosis (DVT) and pulmonary embolism
(PE), is a common complication observed in patients
with metastatic bone disease (MBD). Despite the wellknown association between cancer and VTE, the
mechanism promoting this pathology is not entirely
well understood. In cancer patients, all three aspects of

Virchow’s triad, hemodynamic stasis, endothelial injury,
and hypercoagulability, are likely involved in the promotion
of thromboembolic events (1). In many of these patients,
tumors may compress veins with resultant stasis and cause
a highly hypoxic environment that damages endothelium.
Additionally, abnormalities in the coagulation and
fibrinolytic pathways as well as platelet activation have been
implicated in VTE, and excitation or suppression of these
specific pathways may be tumor dependent (2). Additional

^ ORCID: 0000-0003-0494-2284.

© Annals of Joint. All rights reserved.

Ann Joint 2022;7:39 | https://dx.doi.org/10.21037/aoj-20-107

Page 2 of 8

factors such as radiation therapy to extremities causing
vessel effects may compound these risks. It is estimated that
nearly all cancer patients will experience from some form of
VTE, whether or not clinically relevant, during the course
of their disease. Annually, the incidence of VTE in cancer
patients is 0.5%, much higher than the 0.1% in the general
population (3). There are many risk factors for VTE
including increased age, female sex, black and Hispanic
race, comorbid disease, immobility, and previous history of
VTE (2). Cancer associated thrombosis may be impacted
by various risk factors including a cancer site, advanced
stage, histological subtype, and the time since diagnosis (4).
Additionally, hospitalization time, central venous catheter,
and treatments such as chemotherapy and surgery are wellestablished risk factors for VTE (5).
Numerous studies have analyzed the occurrence and
prevention of VTE in patients with cardiovascular disease or
suffering trauma (6), but very few have specifically examined
the safety or efficacy of preventing VTE in cancer patients
with metastatic skeletal disease. After the lungs and liver, bone
is the third most common site of cancer metastases (7). The
risk of VTE in patients undergoing intramedullary nailing for
metastatic disease involving long bones is known to be high (8).
In a retrospective review of the risk of VTE in patients
undergoing intramedullary nailing for prophylactic fixation
related to skeletal metastases, 203 of 336 patients (60.4%)
received low molecular weight heparin (LMWH), the most
frequently used anticoagulant, followed by 44.6% enoxaparin,
15.8% dalteparin, 16.7% warfarin, 5.4% subcutaneous
heparin, 5.1% aspirin, 0.9% fondaparinux, 0.6% unverifiable
and 11.0% no anticoagulant. In total, 24 VTE events
occurred [13 PEs (3.9%) and 11 DVTs (3.3%)]. Although
the data reflected that LMWH was the most commonly
used anticoagulant in patients that developed VTE, further
data analysis determined that there was no correlation
between the type of anticoagulant used and the occurrence of
VTE (8) in this patient population.
This study highlights both the need for and the
inconsistencies in choice of anticoagulation in this population.
This review will examine the various types of prophylactic
treatment, timing of administration, risk stratification for
determining the appropriate course of anticoagulation (AC)
and discuss current views on chemical prophylaxes relativity
to wound complications and excessive bleeding.
Mechanical, chemical and combination prophylaxis
Cancer and orthopedic surgery are known risk factors for
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VTE (9), and therefore the need for prophylactic treatment
aimed at preventing the occurrence of VTE in these patient
populations is well understood (10). However, the ideal
choice of prophylactic treatment for patients undergoing
surgery for skeletal metastases is unknown.
Mechanical prophylaxis
Mechanical prophylaxis, either alone or in combination
with chemical prophylaxis, in patients undergoing
orthopedic surgery is widely accepted due to minimal risk of
serious complications with use (11). Woolson et al. studied
the use of intermittent pneumatic sequential compression
devices (SCD) to prevent proximal DVT during and after
hip replacement. Patients were randomized to one of
three cohorts: SCD alone, SCD plus aspirin, or SCD plus
low dose heparin, in an effort to examine the true efficacy
of mechanical prophylaxis alone or in combination with
chemical prophylaxis. The results of the study supported
the argument that mechanical prophylaxis alone was
effective, safe and convenient with respect to preventing
proximal DVT during and after hip replacement (11).
However, although partial or total hip replacement is a
common procedure in patients with MBD, the results of
this study may not be applicable to the MBD population.
Lin et al. conducted a prospective study assessing the risk of
VTE in patients undergoing major orthopedic surgery of
the lower limb for which knee-high pneumatic compression
stockings were used prophylactically in combination with
ultrasound screening. The rate of symptomatic PE was low,
but the risk of DVT was significant (10). In fact, the risk of
proximal DVT was substantial even when combined with
chemical prophylaxis (10). One study addresses the use of
mechanical prophylaxis alone in patients who underwent
resection of musculoskeletal tumors of the lower limb:
DVT was detected in 21 (22%) patients of the 94 patients
who underwent resection of a lower limb musculoskeletal
tumor. In addition, one patient experienced a fatal PE.
The conclusion was drawn that the use of monotherapy
mechanical prophylaxis was an insufficient means of
preventing VTE in this population (12).
Chemical prophylaxis
Surgery for malignant disease increases the risk of VTE
nearly two-fold compared to patients undergoing non-cancer
related orthopaedic surgery (13). Additionally, patients
with cancer are more likely to experience recurrence of

Ann Joint 2022;7:39 | https://dx.doi.org/10.21037/aoj-20-107

Annals of Joint, 2022

VTE than those without (13). Thus, since about 2004 all
major orthopaedic patients were recommended to receive
postoperative chemoprophylaxis (14). However, which type
of chemical prophylaxis remains widely debated both for
efficacy and safety.
Vitamin K antagonists (VKAs), such as warfarin, were
once considered the gold standard for VTE prevention.
The risk of VTE was felt to outweigh the potential for
excessive bleeding complications, so patients received
VKAs both post-operatively as well as for conventional
long-term management of VTE. However, the extensive
list of challenges associated with the administration of
VKAs have subsequently led to the increasing popularity
of other options. VKAs demonstrate a known established
risk of an increased anticoagulant effect when combined
with other concomitant therapies (13). There is a long
delay between the initiation of therapy and the observed
anticoagulant effect, which in some cases may require or
prolong an inpatient hospital stay (13). Whether or not
VTE occurs, the administration of VKAs long-term postoperatively requires continuous lab monitoring (13). The
patient’s location may play a role in non-compliance by
making it difficult or impossible to travel to a lab routinely,
particularly in a post-operative condition, putting the safety
and health of the patient at further risk postoperatively.
LMWH and unfractionated heparin (UFH) have been
proven to be safer than VKAs for long-term management
of VTE from the standpoint of prevention of propagation
or thrombosis recurrence. With a predictable anticoagulant
effect, LMWHs do not require regular lab monitoring, do
not require an in-patient hospital stay to initiate treatment,
and have a rapid onset and offset action translating to
better adaptability when initiating and discontinuing
therapy (13). The CLOT study showed that in cancer
patients with VTE, long term treatment with a LMWH
dalteparin was more effective in reducing the risk of
recurrent VTE than treatment with a VKA along with a
numerically lower risk of any bleeding (13,15). This study,
along with three other randomized clinical trials, form the
primary support for current preference for LMWH agents
for use in treatment of VTE patients with cancer (16-18).
Aspirin is another potential alternative for chemical VTE
prevention, supported primarily in orthopedic literature. A
prospective cross-over study of patients undergoing primary
total joint arthroplasty (TJA) demonstrated aspirin, both
high dose and low dose, is a safe and effective prophylaxis
when used in combination with in-hospital mechanical
prophylaxis for the prevention of VTE (19). Currently
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available literature, not specific to the cancer population,
shows that low-dose aspirin is not inferior to high dose
aspirin for VTE prophylaxis in patients undergoing total
joint arthroplasty (19). Very few studies address the use
of aspirin for VTE prevention specifically in the cancer
population, but one small retrospective review of patients
undergoing surgery for a primary malignant soft-tissue or
bone tumor or metastatic carcinoma, demonstrated that
aspirin may be effective at preventing VTE in patients
undergoing orthopaedic oncologic surgery. Research with
larger numbers and ideally a more advanced study design
should be conducted for further support (20).
More recently, attention has turned to the use of direct
oral anticoagulants (DOACs) in patients with cancer
undergoing surgery. In non-cancer patients, dabigatran and
edoxaban are as effective as VKAs at VTE prevention and
are associated with a lower risk of major bleeding (21). The
2016 American College of Chest Physicians recommends
DOACs such as rivaroxaban and apixaban over VKAs
for treatment of DVT and PE (21). DOACs have a rapid
onset of action and predictable pharmacokinetic profile
thus avoiding an inpatient initiation of treatment, delay
in anticoagulant effects and the necessity for continuous
lab monitoring (21). In addition, administration of an oral
agent is far more convenient than intravenous infusion or a
subcutaneous injection as observed in LMWHs.
Initial support for use of DOACs in patients with
cancer comes primarily from two clinical trials, HokusaiVTE Cancer and Anticoagulation Therapy in Selected
Cancer Patients at Risk of Recurrence of Venous
Thromboembolism (SELECT-D) (22,23). The HokusaiVTE Cancer study looked at edoxaban versus dalteparin
treatment, and found edoxaban to be statistically
noninferior to dalteparin for the composite outcome
of recurrent VTE or major bleeding. Absolute rate of
recurrence of DVT was lower than dalteparin, but absolute
risk of major bleeding was statistically higher, which in
subgroup analysis was shown to be only in patients with
gastrointestinal cancer. The SELECT-D study evaluated
rivaroxaban versus dalteparin. The study demonstrated that
rivaroxaban treatment was associated with a lower rate of
VTE recurrence, equivalent rate of major bleeding, again
primarily in gastrointestinal cancers, and numerically higher
rate of clinically relevant non-major bleeding compared to
dalteparin treatment.
Regarding orthopedic surgery specifically, apixaban
is currently approved for thromboprophylaxis treatment
in both total knee replacement surgery and total hip
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Table 1 Summary of prophylaxis methods’ advantages and disadvantages
Prophylaxis method

Type

Advantages

Disadvantages

Mechanical

Sequential Compression
Device (SCD)

Low cost, no risk

None

Compression stockings

Low cost, no risk

None

Vitamin K antagonists
(VKA)

Low cost; easily reversible

Interaction with other medications;
increased risk for bleeding; delayed onset
of anticoagulation; increased length hospital
stay; continuous lab monitoring

Low molecular weight
heparin (LMWH)

Rapid onset; safer than VKA; no lab
monitoring; no prolonged inpatient stay

Administered via injection; limited use in
renal Insufficiency; risk for HIT

Unfractionated heparin

Rapid onset; safer than VKA

IV administration; risk of HIT; frequent lab
monitoring

Aspirin

Low cost; low risk for bleeding

Administered with use of SCD’s

Direct Oral Anticoagulants
(DOAC)

Low risk for bleeding; rapid onset;
predictable pharmacokinetics; no lab
monitoring; no prolonged inpatient stay;
oral administration

Difficult reversal; expensive

Chemical

HIT, heparin-induced thrombocytopenia.

replacement surgery (24). Adequate study has not been
performed to determine if there is a benefit or drawback
to using these agents versus other agents for prevention
of VTE. Initial data from small retrospective series report
conflicting evidence regarding whether use of DOACs
preoperatively may cause delay of surgery. However,
there is currently no specific antidote to reverse its
anticoagulant effect (24). Additionally, in regards to postoperative resumption of apixaban, there are no definitive
recommendations (24). For low-risk procedures, apixaban
may be resumed within 24 h, for high-risk procedures
apixaban may be resumed within 48–72 h and for patients
unable to take oral medications postoperatively, enoxaparin
40 mg once daily may be used for interim prophylaxis (24).
In addition to inconsistencies in guidelines, access to
DOACs may prove challenging. DOACs for venous
thromboprophylaxis are notoriously more expensive and
therefore a certain subset of patients may have limited
access (21). Thus, the selection and administration of
anticoagulants to patients with cancer undergoing surgery, both
established risk factors, must be carefully considered (Table 1).
Bleeding complications
In orthopedic surgery in particular, a balance must be
struck to effectively prevent VTE and avoid undesired
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wound complications (25,26). The morbidity of wound
complications in orthopedic surgery is severe, in many
cases requiring removal of orthopedic implants, sometimes
without hope of future reimplantation (27). In an attempt to
examine how to achieve this balance, a retrospective study
examining the high risk of VTE after surgery for long bone
metastases, Groot et al. examined the relationship between
wound complication rates and chemoprophylaxis (28).
Patients were chemically anticoagulated postoperatively
with LMWH (358 of 682 patients comprising 52%), no
anticoagulant (113, 17%), warfarin (129, 19%), aspirin
(66, 10%) and subcutaneous heparin (16, 2%). Notably,
compression stockings and compression devices were not
included as variables because they were routinely used at
the hospital in which the study was conducted.
Overall, 6% (44 of 682) of patients had symptomatic
VTE, 22 patients sustained a DVT and 22 patients
developed a PE (28). But most significantly, no association
was found between wound complications and the use of
chemoprophylaxis (P=0.252). Of the 682 patients followed,
9 underwent revision surgery for deep infection, 3 for deep,
large hematoma, and 1 large retroperitoneal hematoma (28).
Similarly, Shallop et. al determined no correlation
between a specific anticoagulant and rate of wound
complications (8). In this study evaluating patients
undergoing intramedullary nailing for metastatic bone
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lesions, the data also reflected no correlation between a
specific anticoagulant and rate of wound complication (8).
Moreover, none of the patients with wound complications
experienced VTE (8). In the patients followed, a total of 11
operations (3.3%) were classified as an infection or “other
wound complications” (8). However, the authors note that
it is possible that this study may have been underpowered to
detect a true difference. The authors also note that the lower
incidence of wound complications in patients undergoing
intramedullary nailing may be attributable to the limited
nature of the incisions in comparison to arthroplasty, and
that in many cases treatment of wound complications with
intramedullary nailing cases can be treated without implant
removal. Therefore, in this population, more aggressive AC
may be acceptable when considering wound risks (8).
Risk stratification
I n p a t i e n t s w i t h c a n c e r, l o w e r e d b l o o d c o u n t s ,
chemotherapy, drug interactions, renal impairment and
hepatic involvement with metastases all contribute to a
higher risk of bleeding complications (14). Influenced
by factors such as cancer type, chemotherapy, surgical
intervention and thrombocytopenia (29), the risk of major
bleeding increases significantly with metastatic disease
and immobility greater than or equal to four days (29).
Currently, there is no bleeding score to assess the risk of
patients with cancer. Thus, an individualized approach
of risk assessment is recommended (29). However, the
implementation of a more standard risk stratification
system, inclusive of patient’s comorbidities, would
potentially decrease the risk of VTE by making the process
of selecting and administering anticoagulants happen
according to a data-driven protocol.
A study examining the potential to decrease the number of
surgically associated thromboembolic events by embedding
a risk stratification tool into the electronic medical record
(EMR) system using Epic Systems Corporation (Epic)
software proved the effectiveness of such a risk stratification
system (30). The site of the study used a tool in Epic to
link a patient’s risk level to specific VTE prophylaxis order
sets. Risk factors for stratification included many factors
including a history of cancer and undergoing a major
operation. When providers were compliant, consistency
and accuracy in AC selection improved thus decreasing
VTE rates (30). A similar study was conducted examining
the benefits of a risk stratification system for the occurrence
of a PE in patients undergoing total joint arthroplasty
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(TJA). In this study, a point scoring system was introduced
to estimate the risk for PE (31). As a result, the point
scoring system was able to help predict the risk for PE after
TJA (31). Findings in other studies have suggested other
risk factors could be added for consideration when building
a stratification system. Due to correlation between primary
lung histology and increased risk of VTE as well as postoperative radiation and an increased risk of VTE, Shallop
et al. suggests AC protocols should be adjusted to a patient’s
primary disease (8). Similarly, Ratasvuori et al. determined
intraoperative oxygen saturation drop, pulmonary
metastases and intramedullary nailing were all independent
risk factors for VTE (14). These factors, as well as many
others, could be built into a risk stratification system to
help tailor anticoagulant regimens even more specifically to
patients with MBD and other comorbidities thus effectively
decreasing the occurrence of VTE.
Timing of prophylactic treatment
In an early retrospective study, De la Garza Ramos et al.
investigated the effect of timing of initiation of prophylactic
AC on the incidence of VTE after surgery for metastatic
tumors of the spine, where bleeding complications could
be disastrous (32). Out of 65 patients included for the
purpose of the study, 36/65 (56%) received prophylactic
AC in addition to mechanical prophylaxis between days
1 and 3 after surgical intervention. With only one case
of an epidural hematoma (1.5%), the results of the study
showed a significant reduction in the risk of DVT and PE
occurring within 30 days for patients undergoing surgery
for metastatic tumors of the spine (32). Although further
research was encouraged, the findings preliminarily showed
that “early” prophylactic AC post-operatively is reasonably
safe and potentially decreased the risk of VTE events (32).
In a similar but more recent study examining the risk for
VTE in patients undergoing surgery for metastatic disease
of the spine, all chemoprophylaxis was started within
48 hours after surgery. Contrary to the previous study, in
this population, a significant 11% of patients experienced
symptomatic VTE (6% PE and 6% DVT) and overall 10%
of patients developed a wound complication including 1.1%
spinal epidural hematomas (25).
In patients undergoing surgery for non-spinal skeletal
metastasis largely due to pathological fractures, a significant
10% of patients experienced symptomatic VTE with an
overall incidence of 3.3% fatal PE (14). As a result, the
author implored greater collaboration for appropriate
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Patient with skeletal metastasis

Needs extremity surgery (stabilization or joint replacement)?
Yes

No

Other risk factors for VTE?

Mechanical prophylaxis during
periods of immobility

Yes

SCD during hospitalization

No

SCD during hospitalization

+

+

ASA, DOAC, or LMWH

DOAC or LMWH

Immediately postoperatively

Immediately postoperatively

and continue for 30 days or

and continue for 30 days or

longer if still immobile

longer if still immobile

For spine patients may delay

For spine patients may delay

start up to 48 hours

start up to 48 hours
If VTE develops, then stop
prophylactic dosing and switch to
treatment dosing, consider Filter

Figure 1 Algorithm for venous thromboembolism prophylaxis in orthopedic oncology patients. VTE, venous thromboembolism; SCD,
sequential compression device; ASA, acetylsalicylic acid; DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin.

risk stratification of patients between hematologists and
orthopaedic oncology surgeons (14), and with respect to
timing of AC, raises the issue of preoperative anticoagulation.
Administration of preoperative anticoagulants was previously
feared for high risk of infection, increased bleeding and
other complications. However, in a single institution
prospective study evaluating the safety and efficacy of
adding pre and post AC in major non-orthopedic surgery,
Selby et al. found no significant increase in bleeding
complication between those that received anticoagulants
preoperatively and those that did not (33). Additionally,
the study showed that in patients undergoing major cancer
surgery, a single dose of a preoperative chemoprophylaxis
did not increase bleeding or blood transfusions (33).
When comparing those that did not receive preoperative
chemoprophylaxis, and those that did in the form of UFH
(5,000 U) or LMWH (40 mg enoxaparin) within 2 h prior
to the operation, the cohort that did receive preoperative
chemoprophylaxis had significantly lower rates of bleeding
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complications, blood transfusions, DVT and PE (33). Thus,
the benefits of preoperative chemoprophylaxis at preventing
the occurrence of VTE seem to outweigh the minimal risk
of excessive bleeding. Further study will need to be done to
evaluate this strategy in the MBD surgical population.
Conclusions
With a reported 84% of patients with breast or prostate
cancer displaying skeletal deposits at post mortem (7), the
impact of metastatic skeletal disease is staggering. Metastatic
skeletal disease, commonly requiring orthopaedic surgery,
puts patients a high risk of VTE. As such, a variety of
chemical anticoagulants are effective, particularly when
administered sooner rather than later, at reducing the risk
of VTE. Careful choice of anticoagulant and timing of
administration must be made in order to avoid bleeding
complications (Figure 1). A risk stratification system to
determine which chemical prophylaxis to administered could
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be beneficial in both reducing the occurrence of VTE and
decreasing associated wound complications or mortality.
Further study should be conducted to tailor chemical
prophylaxes recommendations to this largely affected
population and effectively reduce the occurrence of VTE.
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